Wells Fargo raises United Therapeutics stock price target on ILD outlook
Wells Fargo raised its price target for United Therapeutics (UTHR) to $703, citing strong momentum and positive KOL feedback on TreSMI. The stock is near its 52-week high, with a 25% YTD return. Q3 revenue was $832.5M, beating estimates, but EPS missed. Tyvaso revenue grew 11% QoQ. Raymond James also raised its target to $720.
How this was made
The 30-second read
Why it matters
Analyst upgrades and a modest price‑target increase reflect confidence in revenue growth, but the EPS miss introduces caution.
Market read
Earnings release provides new data that may influence short‑term trading decisions on UTHR.
What to watch
Potential future growth from the delayed TreSMI launch and continued demand for Tyvaso may support longer‑term upside.
Background
United Therapeutics reported strong Q3 revenue driven by its Tyvaso product, while earnings per share fell short of forecasts.
Ticker impact
Wells Fargo raised its price target on United Therapeutics to $703 and reported a record Q3 revenue of $832.5M, but EPS missed expectations at $5.71 vs $6.21.
likely pressure as investors weigh the earnings miss against the revenue beat and target raise
Revenue beat supports upside, but EPS shortfall and modest target lift suggest limited upside and possible short‑term downside.
Market effects
Positive signal for the pulmonary‑hypertension drug segment, but earnings miss may temper broader biotech sentiment.
Limited to U.S. biotech stocks; no broader regional effect.
Minimal; primarily affects United Therapeutics and peers.
Counterpoint
The revenue beat could outweigh the EPS miss, allowing the stock to rally on the price‑target raise.
Key entities
- companyUnited Therapeutics Corp.
Biopharma company focused on pulmonary‑hypertension therapies.
- analystWells Fargo
Raised price target on United Therapeutics to $703.
